FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

With bids due today, Solvay mulls options

Tools

Will Solvay--or won't it? Preliminary offers for its pharmaceutical unit are due today, Reuters reports, which means we could know fairly soon whether the Belgian company will go ahead with a sale. Solvay hired Citigroup to take a look at various options for its pharma unit; everything from growing the business via acquisitions to selling it off completely.

And you'll recall that Sanofi-Aventis reportedly approached Solvay about buying the pharma business. Among other interested parties, sources tell Reuters, is Novartis. Analysts tagged Bayer as another potential buyer. Companies that aren't bidding: Abbott Laboratories, Solvay's TriCor partner; and Takeda Pharmaceutical, which denied reports that it was interested in a deal.

Another question appears to be whether Solvay will be broken up for sale or go to one buyer lock, stock and barrel. The company has a flu-vaccine business--Solvay Biologicals--that could be very attractive to some buyers, especially in the midst of a global outbreak of novel flu, the news service said.

- read the Reuters story
- check out Takeda's denial of interest, also from Reuters

Related Articles:
Solvay sale isn't on the fast track
Solvay bidders, start your engines
Solvay: Yes, we're reviewing our strategies
Sanofi nabs Mexican drugmaker, eyes Solvay
Solvay shops for buyers for its pharma unit 


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Comments (1) | Post a comment
More stories about Mergers and Acquisitions   Solvay   strategic options  

Comments

I hear of a potential Solvay Bayer merger!!!!!

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.